噬菌体疗法的药代动力学/药效学:临床转化的主要障碍
本文为叙述性综述,检索PubMed和Google Scholar至2022年6月,讨论噬菌体药代动力学(吸收、分布、代谢、消除)及影响抗菌活性的关键因素,强调噬菌体自我复制对PK/PD的影响及PK/PD建模所需的基本特征。噬菌体药理学虽有进展,但相比抗生素仍处起步阶段,优化PK/PD是临床转化的关键。
要点
- 噬菌体疗法缺乏PK/PD信息是临床转化的主要挑战。
- 噬菌体在易感细菌存在下可自我复制,其PK/PD远比抗生素复杂。
- 优化噬菌体PK/PD是患者临床转化的关键。
核心结论
- 噬菌体药理学近年有进展,但相比抗生素仍处起步阶段,原因是药理学知识(如PK/PD)稀缺。
- 优化噬菌体PK/PD是噬菌体疗法在患者中临床转化的关键。
研究设计与样本
- 叙述性综述,检索PubMed和Google Scholar至2022年6月,检索词为「bacteriophage」「antimicrobial」「pharmacokinetics」「pharmacodynamics」,并从主要检索所得文章中获取额外相关参考文献。
主要发现
- 噬菌体PK讨论聚焦吸收、分布、代谢和消除。
- 影响噬菌体抗菌活性的关键因素包括感染复数、被动与主动噬菌体疗法以及人体免疫系统的参与。
- 噬菌体自我复制影响PK/PD,且PK/PD建模和临床转化需要噬菌体具备基本特征。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The increasing emergence of antimicrobial resistance worldwide has led to renewed interest in phage therapy. Unlike antibiotics, the lack of pharmacokinetics/pharmacodynamics (PK/PD) information represents a major challenge for phage therapy. As therapeutic phages are biological entities with the ability to self-replicate in the presence of susceptible bacteria, their PK/PD is far more complicated than that of antibiotics. OBJECTIVES: This narrative review examines the current literature on phage pharmacology and highlights major pharmacological challenges for phage therapy. SOURCES: Included articles were identified by searching PubMed and Google Scholar till June 2022. The search terms were 'bacteriophage', 'antimicrobial', 'pharmacokinetics' and 'pharmacodynamics'. Additional relevant references were obtained from articles retrieved from the primary search. CONTENT: In this review, phage PK is first discussed, focusing on absorption, distribution, metabolism, and elimination. Key factors affecting phage antimicrobial activities are reviewed, including multiplicity of infection, passive and active phage therapy, and the involvement of the human immune system. Importantly, we emphasize the impact of phage self-replication on the PK/PD and the fundamental phage characteristics that are required for PK/PD modelling and clinical translation. IMPLICATIONS: Recent progress in phage pharmacology has shown that we are in a far better position now to treat infections with phage therapy than a century ago. However, phage therapy is still in its infancy when compared to antibiotics due to the scarce pharmacological knowledge (e.g. PK/PD). Optimization of phage PK/PD is key for translation of phage therapy in patients.
引用
- Nang SC, Lin YW, Petrovic Fabijan A, et al. Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation. Clin Microbiol Infect. 2023. PMID: 36736661. doi:10.1016/j.cmi.2023.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。